For the year ending 2025-12-31, MTNB has $7,208K in assets. $2,378K in debts. $3,999K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 3,999 | |||
| Restricted cash security deposit | 50 | |||
| Prepaid expenses and other current assets | 26 | |||
| Total current assets | 4,075 | |||
| Leasehold improvements and equipment - net | 138 | |||
| Operating lease right-of-use assets - net | 531 | |||
| Finance lease right-of-use assets - net | 4 | |||
| In-process research and development | 2,260 | |||
| Restricted cash - security deposit | 200 | |||
| Total non-current assets | 3,133 | |||
| Total assets | 7,208 | |||
| Accounts payable | 315 | |||
| Accrued expenses and other liabilities | 452 | |||
| Operating lease liabilities - current | 694 | |||
| Financing lease liabilities - current | 2 | |||
| Total current liabilities | 1,463 | |||
| Deferred tax liability | 257 | |||
| Operating lease liabilities - net of current portion | 653 | |||
| Financing lease liabilities - net of current portion | 5 | |||
| Total non-current liabilities | 915 | |||
| Total liabilities | 2,378 | |||
| Common stock par value 0.0001 per share, 500,000,000 and 250,000,000 shares authorized at december 31, 2025 and 2024, respectively 6,406,191 and 5,086,985 issued and outstanding as of december 31, 2025 and 2024, respectively | 1 | |||
| Additional paid-in capital | 215,616 | |||
| Accumulated deficit | -210,787 | |||
| Total stockholders equity | 4,830 | |||
| Total liabilities and stockholders equity | 7,208 | |||
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)